Literature DB >> 1504638

Effects of nicotine on subjective arousal may be dependent on baseline subjective state.

K A Perkins1, J E Grobe, L H Epstein, A R Caggiula, R L Stiller.   

Abstract

The often disparate and contrasting effects of nicotine on subjective arousal in smokers may be due in part to differences in presmoking subjective state. In Study 1, on each of 2 days, 10 male smokers were divided into high- and low-baseline subgroups on the basis of median split of resting predrug baseline subjective arousal. Then, subjects received intermittent nicotine (15 mu/kg) or placebo via measured-dose nasal spray, with drug conditions counterbalanced between days. In Study 2, 32 male and female smokers were similarly divided into high- and low-baseline subgroups on subjective arousal prior to either smoking or sham-smoking (n = 16 each) during a single session. Results were virtually identical between studies in showing that subjective arousal responses to nicotine (Study 1) or smoking (Study 2) were significantly inversely related to baseline arousal level; those initially low in arousal showed large increases following nicotine or smoking whereas those high in arousal showed little change. No such baseline dependency of responses was seen following placebo or sham smoking. Baseline dependency of cardiovascular responses to nicotine or smoking was also evaluated in similar fashion to determine generalizability of these effects to nonsubjective responses. In each study, systolic blood pressure response was related to baseline level but there was no effect of baseline level on heart rate and diastolic blood pressure responses. Implications of these results for explaining differential rewarding effects of smoking are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1504638     DOI: 10.1016/0899-3289(92)90013-n

Source DB:  PubMed          Journal:  J Subst Abuse        ISSN: 0899-3289


  9 in total

1.  Methodological considerations in nicotine research: the use of "denicotinised" cigarettes as the control condition in smoking studies.

Authors:  J M Rusted; L Graupner; K Greenwood
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

Review 2.  The addictive role of nicotine in tobacco use.

Authors:  J E Henningfield; S J Heishman
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

3.  Acute pharmacodynamic tolerance to the subjective effects of cigarette smoking.

Authors:  A C Parrott
Journal:  Psychopharmacology (Berl)       Date:  1994-09       Impact factor: 4.530

4.  Individual differences in stress and arousal during cigarette smoking.

Authors:  A C Parrott
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

Review 5.  Individual variability in responses to nicotine.

Authors:  K A Perkins
Journal:  Behav Genet       Date:  1995-03       Impact factor: 2.805

6.  Subjective and cardiovascular responses to nicotine combined with alcohol in male and female smokers.

Authors:  K A Perkins; J E Sexton; A DiMarco; J E Grobe; A Scierka; R L Stiller
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

7.  Smoking is associated with worse mood on stressful days: results from a national diary study.

Authors:  Keith R Aronson; David M Almeida; Robert S Stawski; Laura Cousino Klein; Lynn T Kozlowski
Journal:  Ann Behav Med       Date:  2008-12-06

8.  Subjective and cardiovascular responses to nicotine combined with caffeine during rest and casual activity.

Authors:  K A Perkins; J E Sexton; R L Stiller; C Fonte; A DiMarco; J Goettler; A Scierka
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

9.  The role of the SLC6A3 3' UTR VNTR in nicotine effects on cognitive, affective, and motor function.

Authors:  Rebekka Schröder; Martin Reuter; Kaja Faßbender; Thomas Plieger; Jessie Poulsen; Simon S Y Lui; Raymond C K Chan; Ulrich Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2021-12-02       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.